Clinical trials: Immune System Suppression
HIV Infections
Combination Vaccination Before HIV Treatment Interruption
The purpose of this study is to determine if vaccination before a structured treatment interruption (STI) is associated with an improvement in immune function, resulting in a delayed and reduced rebound in the amount of HIV virus…
- Trial name
- NCT00212888
- Testing
- Remune and ALVAC
- Where
- 3 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Ottawa Hospital Research Institute
Scleroderma, Systemic
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
ASSIST I was the first randomized trial in patients with scleroderma to not just slow disease progression but rather actually reverse it.
- Trial name
- DIScl2011 (NCT01445821)
- Testing
- Peripheral Blood Stem Cells, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
HIV Infections
Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
This pilot study focuses on the persistence of central nervous system (CNS) immune activation that has been observed in the presence of 'effective' combination antiretroviral therapy (cART).
- Trial name
- NCT00672932
- Testing
- raltegravir
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Heart Diseases, Heart Transplantation
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
The purpose of this study is to assess the safety and efficacy of tacrolimus in de novo heart transplantation.
- Trial name
- NCT00157014
- Testing
- Tacrolimus, Cyclosporine, Mycophenolate mofetil
- Where
- 13 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Astellas Pharma Inc
Living Donor Liver Transplantation
DCreg in Living Donor Liver Transplantation
Phase I/II, single center, prospective, open-label, non-controlled, non-randomized, interventional, cohort study in which low risk living donor liver transplant (LDLT) recipients will receive a single infusion of donor-derived…
- Trial name
- NCT03164265
- Testing
- Regulatory Donor-Derived Dendritic Cell infusion
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Angus W. Thomson PhD DSc
Other Complication of Kidney Transplant, Renal Transplant Rejection
Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients
Steroids are one of the pillars of immunosuppression for kidney transplant patients but their use is associated with a high rate of complications.
- Trial name
- NCT02284464
- Testing
- Prednisone withdrawal, Prednisone continuation
- Where
- 5 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
- Trial name
- ENDURE (NCT01090310)
- Testing
- AIN457
- Where
- 35 sites in United States, Brazil and 6 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Allogeneic Stem Cell Transplantation, Refractory Autoimmune Cytopenia(s)
Bortezomib to Treat Significant Complication of HSCT
The purpose of this trial is to study the safety and effectiveness of a drug called Bortezomib for the treatment of low blood cell counts after bone marrow transplant.
- Trial name
- Bortezomib (NCT01929980)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Liver Transplant, Liver Transplantation
Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients
Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ.
- Trial name
- WISP-R (NCT00320606)
- Testing
- Immunosuppression Withdrawal
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Carcinoma
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.
- Trial name
- NCT00328770
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University of Alberta
Diabetes Mellitus, Insulin-Dependent
Islet Transplantation for Type 1 Diabetes
The purpose of this study is to test whether the islet cell transplantation procedures and results from a previous study in Edmonton, Canada, can be repeated.
- Trial name
- NCT00014911
- Testing
- Islet Transplantation, Sirolimus, Tacrolimus
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1
This was a prospective, non-interventional, single-arm, multi-center study aimed at gathering real-world data on JULUCA use in routine clinical care in Germany, to supplement clinical trial data to further improve/optimize care…
- Trial name
- JUNGLE (NCT03518060)
- Testing
- JULUCA
- Where
- 23 sites in Germany
- Volunteers
- 209 people
- Sponsor
- ViiV Healthcare
Sepsis
Project 4A: Inspiratory Muscle Training and Diaphragm Strength
Investigators will assess the effect of exercise on markers of inflammation and protein catabolism. This research study will further our understanding of how treating Chronic Critical illness (CCI) - related respiratory muscle…
- Trial name
- NCT02367170
- Testing
- Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure, Midazolam, Volitional Measurement of Maximal Inspiratory Pressure (MIP)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
HIV Infections, Herpes Simplex
HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding
In this study, we will determine whether treating pregnant and breastfeeding women co-infected with human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) with daily valacyclovir will reduce HIV-1…
- Trial name
- VIP (NCT00530777)
- Testing
- valacyclovir
- Where
- Kenya
- Volunteers
- 148 people
- Sponsor
- University of Washington
Liver Disease, Liver Transplantation
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. Tacrolimus is a drug used to decrease immune system activity in people who have received organ transplants so that the new organ will not be rejected.
- Trial name
- TILT (NCT00105235)
- Testing
- Alemtuzumab, Cyclosporine, Mycophenolate mofetil
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunosuppression
Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Biomedical Lay Summary Title: Characterization of immune response to vaccination in patients receiving single-drug immunosuppressive therapy Principal Investigator: Robert Swerlick, MD Other Investigators: Rafi Ahmed, PhD Suephy…
- Trial name
- NCT01733056
- Testing
- Flu Vaccine
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Emory University
Kidney Transplantation
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection.
- Trial name
- NCT00483756
- Testing
- Cyclosporine, CP-690,550
- Where
- 69 sites in United States, Australia and 13 more
- Volunteers
- 338 people
- Sponsor
- Pfizer
Kidney Transplantation
A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
- Trial name
- NCT01820572
- Testing
- Belatacept, Tacrolimus, Cyclosporine
- Where
- 117 sites in United States, Argentina and 8 more
- Volunteers
- 446 people
- Sponsor
- Bristol-Myers Squibb
Hematologic Malignancies
Phase II Trial of Pentostatin and Targeted Busulfan
The objective of this trial is to determine whether a regimen of pentostatin and busulfan (IV) can facilitate engraftment of human leukocyte antigen (HLA) partially compatible siblings and unrelated donor transplants by using…
- Trial name
- Pento & tBU (NCT00496340)
- Testing
- Pentostatin, Busulfan, Rituximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Leukemia, Acute Myeloid Leukemia
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
There is no curative therapy once acute leukemia patients relapse after transplant. Patients who develop clinically significant graft versus host disease (GVHD) have a lower rate of relapse than those who do not develop GVHD.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia
- Trial name
- NCT01036009
- Testing
- Withdrawal of immunosuppression and donor lymphocyte infusion
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco